Contineum Therapeutics, Inc.
CTNMFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Contineum Therapeutics, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: Contineum Therapeutics, Inc. — 10-K filed Mar 6, 2025
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 3 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 26, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Federation des caisses Desjardins du Quebec | 2026-03-31 | 1,280 | $16.7K | SEC filing |
| Ikarian Capital, LLC | 2026-03-31 | 807,874 | $10.6M | SEC filing |
| XTX Topco Ltd | 2026-03-31 | 35,846 | $468K | SEC filing |
| Boxer Capital Management, LLC | 2026-03-31 | 494,000 | $6.45M | SEC filing |
| Mirae Asset Global Investments Co., Ltd. | 2026-03-31 | 1,588 | $20.7K | SEC filing |
| Quadrature Capital Ltd | 2026-03-31 | 12,799 | $167K | SEC filing |
| CITIGROUP INC | 2026-03-31 | 8,860 | $116K | SEC filing |
| SILVERARC CAPITAL MANAGEMENT, LLC | 2026-03-31 | 301,729 | $3.94M | SEC filing |
| MARSHALL WACE, LLP | 2026-03-31 | 226,302 | $2.96M | SEC filing |
| US BANCORP \DE\ | 2026-03-31 | 123 | $1.61K | SEC filing |
| FMR LLC | 2026-03-31 | 814,871 | $10.6M | SEC filing |
| Trexquant Investment LP | 2026-03-31 | 47,746 | $624K | SEC filing |
| NORTHERN TRUST CORP | 2026-03-31 | 65,928 | $861K | SEC filing |
| CWM, LLC | 2026-03-31 | 1,145 | $15K | SEC filing |
| GOLDMAN SACHS GROUP INC | 2026-03-31 | 307,108 | $4.01M | SEC filing |
| FRANKLIN RESOURCES INC | 2026-03-31 | 1,839,227 | $24M | SEC filing |
| HRT FINANCIAL LP | 2026-03-31 | 22,170 | Not shown | SEC filing |
| Brevan Howard Capital Management LP | 2026-03-31 | 42,178 | $551K | SEC filing |
| INDEPENDENT FINANCIAL GROUP, LLC | 2026-03-31 | 27,021 | $353K | SEC filing |
| ACADIAN ASSET MANAGEMENT LLC | 2026-03-31 | 54,068 | Not shown | SEC filing |
- Each value is checked against Contineum Therapeutics, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 2 rows: the filed value is about 1,000 times too small for the share count at Contineum Therapeutics, Inc.'s share price.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- GF FUND MANAGEMENT CO. LTD.: 454 shares reported 2025-12-31; 513 shares reported 2026-03-31.
- Cornerstone Financial Management LLC: 64 shares reported 2025-12-31; 64 shares reported 2026-03-31.
- Eversept Partners, LP: 137,493 shares reported 2025-12-31; 146,411 shares reported 2026-03-31.
- OMERS ADMINISTRATION Corp: 34,900 shares reported 2025-12-31; 14,200 shares reported 2026-03-31.
- MORGAN STANLEY: 124,286 shares reported 2025-12-31; 70,801 shares reported 2026-03-31.
- Longaeva Partners L.P.: 470,000 shares reported 2025-12-31; 732,088 shares reported 2026-03-31.
- BOOTHBAY FUND MANAGEMENT, LLC: 72,494 shares reported 2025-12-31; 222,329 shares reported 2026-03-31.
- Casdin Capital, LLC: 148,333 shares reported 2025-12-31; 148,333 shares reported 2026-03-31.
- Strategies Wealth Advisors, LLC: 50,000 shares reported 2025-12-31; 50,000 shares reported 2026-03-31.
- MILLENNIUM MANAGEMENT LLC: 830,687 shares reported 2025-12-31; 1,535,449 shares reported 2026-03-31.
- JANE STREET GROUP, LLC: 27,945 shares reported 2025-12-31; 107,380 shares reported 2026-03-31.
- UBS Group AG: 199,389 shares reported 2025-12-31; 230,409 shares reported 2026-03-31.
Showing the 12 most recent filer reports.
64 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Contineum Therapeutics, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-02-24 · Stengone Carmine N.: Larger than 22 of the 23 other insider sales of Class A Common Stock on file. SEC filing
- 2026-02-24 · Lorrain Daniel S.: Larger than 21 of the 23 other insider sales of Class A Common Stock on file. SEC filing
- 2024-11-18 · Lorrain Daniel S.: Larger than all 23 other insider sales of Class A Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-01 | Lorrain Daniel S. · Chief Scientific Officer | Class A Common Stock | S — Open market or private sale | −4,170 | 13.16 | SEC filing |
| 2026-05-01 | Lorrain Daniel S. · Chief Scientific Officer | Class A Common Stock | S — Open market or private sale | −3,870 | 13.06 | SEC filing |
| 2026-05-01 | Lorrain Daniel S. · Chief Scientific Officer | Class A Common Stock | S — Open market or private sale | −300 | 13.84 | SEC filing |
| 2026-04-06 | Lorrain Daniel S. · Chief Scientific Officer | Class A Common Stock | S — Open market or private sale | −4,170 | 13.43 | SEC filing |
| 2026-03-02 | Lorrain Daniel S. · Chief Scientific Officer | Class A Common Stock | S — Open market or private sale | −4,170 | 15.01 | SEC filing |
| 2026-03-02 | Watkins Tim · CMO & Head of Development | Class A Common Stock | S — Open market or private sale | −3,611 | 15.02 | SEC filing |
| 2026-02-25 | Stengone Carmine N. · CEO and President | Class A Common Stock | S — Open market or private sale | −2,700 | 16.02 | SEC filing |
| 2026-02-25 | Lorrain Daniel S. · Chief Scientific Officer | Class A Common Stock | S — Open market or private sale | −3,824 | 16.01 | SEC filing |
Showing 8 of 10 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-26 | Brady Todd R. · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +19,000 | SEC filing |
| 2026-06-26 | Miralles Gines Diego · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +19,000 | SEC filing |
| 2026-06-26 | Schimmelpennink Evert B. · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +19,000 | SEC filing |
| 2026-06-26 | Ignelzi Troy A. · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +19,000 | SEC filing |
| 2026-06-26 | Boyce Sarah · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +19,000 | SEC filing |
| 2026-06-26 | Lyons-Williams Lori · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +19,000 | SEC filing |
| 2026-06-26 | Ware Olivia C · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +19,000 | SEC filing |
| 2026-03-02 | Watkins Tim · CMO & Head of Development | Stock Option (right to buy) | M — Exercise or conversion of derivative security | −3,611 | SEC filing |
Showing 8 of 20 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.